JMP Securities Bullish on Pharmasset, Inc. (NASDAQ: VRUS)

JMP Securities today came up with their Weekly HCV Newsletter, where they reiterate their Market Outperform rating on Pharmasset, Inc. (NASDAQ: VRUS) and price target increased from $23 to $27.

Pharmasset, along with Roche reported that the Data Monitoring Committee (DMC) determined that RG7128's safety profile was acceptable for continued development in the phase IIb trial that reduces clinical risk. Analysts feel that this will help Pharmasset to reduce its risk.

Pharmasset is up 2.84% to $20.29 in the pre-market session. The 52-week trading range for VRUS is $ $7.62 - $24.60. So far this year, VRUS is up over 50%.